BR112022016574A2 - Peptídeos e proteínas projetadas para a detecção, prevenção e tratamento da doença de coronavirus, 2019 (covid-19) - Google Patents

Peptídeos e proteínas projetadas para a detecção, prevenção e tratamento da doença de coronavirus, 2019 (covid-19)

Info

Publication number
BR112022016574A2
BR112022016574A2 BR112022016574A BR112022016574A BR112022016574A2 BR 112022016574 A2 BR112022016574 A2 BR 112022016574A2 BR 112022016574 A BR112022016574 A BR 112022016574A BR 112022016574 A BR112022016574 A BR 112022016574A BR 112022016574 A2 BR112022016574 A2 BR 112022016574A2
Authority
BR
Brazil
Prior art keywords
prevention
treatment
detection
covid
proteins
Prior art date
Application number
BR112022016574A
Other languages
English (en)
Inventor
Yi Wang Chang
Lin Feng
Ding Shuang
Peng Wen-Jiun
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Publication of BR112022016574A2 publication Critical patent/BR112022016574A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

PEPTÍDEOS E PROTEÍNAS PROJETADAS PARA A DETECÇÃO, PREVENÇÃO E TRATAMENTO DA DOENÇA DE CORONAVIRUS, 2019 (COVID-19). A presente divulgação se refere a um sistema de alívio para a detecção, prevenção e tratamento eficazes de COVID-19, incluindo (1) ensaios de diagnóstico sorológico para a detecção de infecção viral e vigilância epidemiológica, (2) construtos de imunógeno de peptídeo de alta precisão, direcionados para o sítio para a prevenção de infecção por SARS-CoV-2, (3) terapias antivirais baseadas em receptor para o tratamento da doença em pacientes infectados e (4) vacina de proteína projetada contendo S1-RBD-sFc. O sistema de alívio divulgado utiliza sequências de aminoácidos de proteínas SARS-CoV-2, bem como receptores humanos para o projeto e fabricação de peptídeos antigênicos de SARS-CoV-2 ideais, construtos de imunógeno de peptídeo, construtos de imunógeno de proteína derivada de CHO, proteínas ACE2 derivadas de CHO de longa ação e suas formulações, como diagnósticos, vacinas e terapias antivirais para a detecção, prevenção e tratamento de COVID-19.
BR112022016574A 2020-02-19 2021-02-19 Peptídeos e proteínas projetadas para a detecção, prevenção e tratamento da doença de coronavirus, 2019 (covid-19) BR112022016574A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062978596P 2020-02-19 2020-02-19
US202062990382P 2020-03-16 2020-03-16
US202063027290P 2020-05-19 2020-05-19
US202063118596P 2020-11-25 2020-11-25
PCT/US2021/018855 WO2021168305A1 (en) 2020-02-19 2021-02-19 Designer peptides and proteins for the detection, prevention and treatment of coronavirus disease, 2019 (covid-19)

Publications (1)

Publication Number Publication Date
BR112022016574A2 true BR112022016574A2 (pt) 2023-02-14

Family

ID=77392273

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016574A BR112022016574A2 (pt) 2020-02-19 2021-02-19 Peptídeos e proteínas projetadas para a detecção, prevenção e tratamento da doença de coronavirus, 2019 (covid-19)

Country Status (10)

Country Link
US (1) US20230109393A1 (pt)
EP (1) EP4107180A4 (pt)
JP (1) JP2023515800A (pt)
KR (1) KR20220144829A (pt)
AU (1) AU2021222039A1 (pt)
BR (1) BR112022016574A2 (pt)
CA (1) CA3172443A1 (pt)
MX (1) MX2022010118A (pt)
TW (1) TWI818236B (pt)
WO (1) WO2021168305A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021207209A2 (en) * 2020-04-06 2021-10-14 The Trustees Of Columbia University In The City Of New York Peptides for detection and differentiation of antibody responses to sars-cov-2 and other human corona viruses
CN113087777B (zh) * 2020-04-17 2023-05-05 成都威斯克生物医药有限公司 抗SARS-CoV-2感染的蛋白以及用该蛋白制备的疫苗
CN115803091A (zh) * 2020-05-22 2023-03-14 福迈康股份公司 Ace2-fc融合蛋白及其用途
WO2021254868A1 (en) * 2020-06-19 2021-12-23 Sciensano Multiplex sars-cov-2 immunoassay
WO2022013609A1 (en) * 2020-07-13 2022-01-20 Immunovaccine Technologies, Inc. Sars-cov-2 vaccine compositions and methods of preparation and use
EP4228697A1 (en) 2020-10-16 2023-08-23 Invisishield Technologies Ltd. Compositions for preventing or treating viral and other microbial infections
MX2023004933A (es) * 2020-10-29 2023-06-06 Formycon Ag Proteinas de fusion de ace2 y usos de las mismas.
CN112852666A (zh) * 2021-01-19 2021-05-28 新疆河润水业有限责任公司 一种微生物菌剂的制备方法及采用微生物菌剂制备的微生物肥料
WO2023034933A1 (en) * 2021-09-02 2023-03-09 Nonigenex, Inc. Methods and systems for assessing adaptive immunity to coronavirus
CN113717258B (zh) * 2021-09-03 2023-09-29 郑州安图生物工程股份有限公司 一种SARS-CoV-2感染细胞免疫检测的抗原多肽组合物及其应用、试剂盒
WO2023044397A1 (en) * 2021-09-15 2023-03-23 The Board Of The Trustees Of The University Of Illinois Engineered receptors and monoclonal antibodies for coronaviruses and uses thereof
CN113769080B (zh) * 2021-09-17 2023-04-07 清华大学 多肽免疫偶联物及其应用
TW202334198A (zh) * 2021-10-12 2023-09-01 聯亞生技開發股份有限公司 用於避免感染與治療遠程新冠肺炎之針對SARS-CoV-2 OMICRON BA.4/BA.5的疫苗組成物
WO2023069461A2 (en) * 2021-10-19 2023-04-27 Vaxxinity, Inc. Method for the prevention and treatment of coronavirus disease
KR20240110821A (ko) * 2021-11-03 2024-07-16 니코데 테라퓨틱스 에이에스에이 SARS-CoV-2로 인한 질병의 예방적 및 치료적 처치에 사용하기 위한 면역원성 작제물 및 백신
GB202117821D0 (en) * 2021-12-09 2022-01-26 Univ Edinburgh A method of providing peptides
WO2023154781A2 (en) * 2022-02-09 2023-08-17 Vaxxinity, Inc. Sars-cov-2 vaccine for the prevention and treatment of coronavirus disease (covid-19)
WO2024011163A1 (en) * 2022-07-06 2024-01-11 Georgia State University Research Foundation, Inc. Coronavirus vaccines and methods of use thereof
WO2024026360A2 (en) * 2022-07-26 2024-02-01 Novavax, Inc. Ace2 inhibition assay for evaluation of vaccine immunogenicity
WO2024118079A1 (en) * 2022-12-01 2024-06-06 Vaxxinity, Inc. Method for the prevention and treatment of coronavirus disease
WO2024138134A2 (en) * 2022-12-22 2024-06-27 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and vaccine for the prevention of coronavirus infection
CN117777309B (zh) * 2023-11-28 2024-10-18 北京吉诺卫生物科技有限公司 一种包括xbbbq11类抗体的融合蛋白构建体、制备方法及其在疫苗中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2553788A1 (en) * 2003-09-29 2006-07-06 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Immunoglobulins whith potent and broad antiviral activity
US20050214748A1 (en) * 2003-11-12 2005-09-29 Wang Chang Y Peptide-based diagnostic reagents for SARS
EP1773388A4 (en) * 2004-06-02 2008-08-20 New York Blood Ct Inc SARS VACCINES AND METHODS OF PRODUCING VERY POWERFUL ANTIBODIES
CN101522208A (zh) * 2005-02-08 2009-09-02 纽约血库公司 抗严重急性呼吸综合征相关冠状病毒的中和单克隆抗体
WO2008060331A2 (en) * 2006-05-19 2008-05-22 Amgen Inc. Antibodies to sars coronavirus
CA2996996A1 (en) * 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
CN106380517B (zh) * 2016-10-28 2019-07-16 中国人民解放军军事医学科学院微生物流行病研究所 一种对中东呼吸综合征冠状病毒具有中和活性的小分子抗体及其应用
US11696948B2 (en) * 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
RU2709659C1 (ru) * 2018-09-06 2019-12-19 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Иммунобиологическое средство и способ его использования для индукции специфического иммунитета к вирусу ближневосточного респираторного синдрома (варианты)
WO2021156490A2 (en) * 2020-02-06 2021-08-12 Vib Vzw Corona virus binders

Also Published As

Publication number Publication date
WO2021168305A1 (en) 2021-08-26
JP2023515800A (ja) 2023-04-14
KR20220144829A (ko) 2022-10-27
CA3172443A1 (en) 2021-08-26
MX2022010118A (es) 2022-09-05
AU2021222039A1 (en) 2022-09-29
EP4107180A1 (en) 2022-12-28
TWI818236B (zh) 2023-10-11
TW202144384A (zh) 2021-12-01
US20230109393A1 (en) 2023-04-06
EP4107180A4 (en) 2024-05-08

Similar Documents

Publication Publication Date Title
BR112022016574A2 (pt) Peptídeos e proteínas projetadas para a detecção, prevenção e tratamento da doença de coronavirus, 2019 (covid-19)
Mohammadi et al. The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines
Treanor et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans
Kam et al. Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein
Badgujar et al. Vaccine development against coronavirus (2003 to present): An overview, recent advances, current scenario, opportunities and challenges
Putnak et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model
Sui et al. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant
Liu et al. Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates
Khan et al. Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice
Levine “IDEAL” vaccines for resource poor settings
Odegard et al. A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs
US20200345829A1 (en) Immunogenic rsv polypeptides
CA2775564A1 (en) Immunopotentiator-linked oligomeric influenza immunogenic compositions
Aaskov et al. Serologically defined linear epitopes in the envelope protein of dengue 2 (Jamaica strain 1409)
Boulter Humoral and cellular aspects of the response to infection: Protection against poxviruses
Lambert et al. A Phase I safety and immunogenicity trial of UBI® microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects
Martin et al. Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus
US12029783B2 (en) Mammary tumor virus vaccine
Tavakol et al. COVID-19 Vaccines in Clinical Trials and their Mode of Action for Immunity against the Virus
CN101300027A (zh) 分泌性IgA和IgG抗体诱导剂
US11780888B2 (en) Chimeric protein for coronavirus vaccine
JP2023528446A (ja) キメラアデノウイルスベクター
Poovorawan et al. Control of a hepatitis A outbreak by active immunization of high-risk susceptible subjects
Zhang et al. Anti-neuraminidase immunity in the combat against influenza
Zandi et al. A snapshot of different types of under research vaccines against COVID-19: a review